section name header

Pronunciation

glye-koe-PYE-roe-late/for-MOE-te-rol

Classifications

Therapeutic Classification: bronchodilators

Pharmacologic Classification: anticholinergics, long-acting beta2-adrenergic agonists (LABAs)

Indications

REMS


Action

  • Glycopyrrolate: acts as an anticholinergic by inhibiting M3 muscarinic receptors in bronchial smooth muscle resulting in bronchodilation; Formoterol: a beta2-adrenergic agonist that stimulates adenyl cyclase, resulting in accumulation of cyclic adenosine monophosphate at beta2—adrenergic receptors resulting in bronchodilation.
Therapeutic effects:
  • Bronchodilation with decreased airflow obstruction.

Pharmacokinetics

Glycopyrrolate

Absorption: Some systemic absorption from lungs and GI tract (40%).

Distribution: Unknown.

Metabolism/Excretion: Primarily metabolized in the liver via the CYP2D6 isoenzyme; eliminated primarily unchanged in the urine and bile.

Half-Life: 33–53 hr.

Formoterol

Absorption: Majority of inhaled drug is swallowed and absorbed.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized by the liver via the CYP2D6 and CYP2C9, and CYP2C19 isoenzymes; 10–18% excreted unchanged in urine.

Half-Life: 10 hr.

Time/Action Profile

(bronchodilation)

ROUTEONSETPEAKDURATION
formoterol—Inhalnwithin 3 min15 minunknown
glycopyrrolate—Inhalnunknownunknownunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: chest pain, hypertension, tachycardia

F and E: hypokalemia

GI: dry mouth, vomiting

GU: urinary tract infection

MS: arthralgia, muscle spasms

Neuro: anxiety, dizziness, headache

Resp: cough, paradoxical bronchospasm

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA, URTICARIA, OR RASH)

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Bevespi Aerosphere